Trudeau also says additional vaccines could be produced in Saskatchewan and Vancouver, but there are no deals with other vaccine makers to use those facilities yet.
The University of Saskatchewan’s Vaccine and Infectious Disease Organization, which received a $46-million funding boost from Ottawa last year, could now produce 40 million doses a year, and Precision NanoSystems in Vancouver, which got a federal grant of $23 million, can produce 240 million doses.
The deal could help Trudeau tamp down the political headache caused by Canada’s skeletal vaccine production capacity.
But Novavax’s vaccine is likely at least two months away from being approved in Canada, while the NRC facility is still under construction and designed to produce only about two million doses a month. Canada has a deal to buy 52 million doses from Novavax after it is approved by Health Canada.
Quebec further delaying second dose of COVID-19 vaccines theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
By Ryan Young
Jan 11, 2021 6:43 PM
It’s expected the clinical trial for the VIDO’s COVID-19 vaccine will begin in the next week in Halifax.
The University of Saskatchewan’s Vaccine and Infections Disease Organization was given the green light for clinical trials just before Christmas.
Director and CEO, Dr. Volker Gerdts, says there is a site initiation visit today (Mon) and paperwork is being finalized.
Phase 1 will include 108 volunteers with the first being in the 18 to 54 age group, then moving to 55 to 69 year olds, followed by those 70 and older.
The testing includes 11 visits to see how the volunteers are doing and to check for any unwanted reactions.
VIDO Intervac vaccine starts clinical trials in Halifax this week By News Room
Jan 11, 2021 10:55 AM
It’s expected the clinical trial for the VIDO’s COVID-19 vaccine will begin in the next week in Halifax.
The University of Saskatchewan’s Vaccine and Infections Disease Organization was given the green light for clinical trials just before Christmas.
Director and CEO, Dr. Volker Gerdts, says there is a site initiation visit Monday and paperwork is being finalized.
Phase one will include 108 volunteers with the first being in the 18 to 54 age group, then moving to the 55 to 69 age group, followed by those 70 and older.
Schools shuttered by fears of a post-holiday pandemic surge reopen in many parts of the country Monday, but experts say keeping kids safe will depend on stepped-up control measures beyond the learning environment.